ATORVALIQ
Peakatorvaliq
NDAORALSUSPENSION
Approved
Feb 2023
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
6/8 — Strong
ATORVALIQ (atorvaliq) is selective, competitive inhibitor of hmg-coa reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme a to mevalonate, a precursor of sterols, including cholesterol. Approved for type 2 diabetes mellitus, heart failure. First approved in 2023.
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ATORVALIQ is an oral suspension formulation of atorvastatin, a selective HMG-CoA reductase inhibitor that lowers cholesterol synthesis and increases hepatic LDL receptor expression. It is indicated for type 2 diabetes mellitus and heart failure, reducing LDL production and particle number.
$0.161MPart D
Peak11.1 years to LOEEarly-stage peak commercial performance with modest claims volume suggests small but growing commercial team focused on differentiation through formulation advantage.
Mechanism of Action
selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. In animal models, atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA…
Indications (2)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.